High-resolution structures of the SARS-CoV-2 2′-O-methyltransferase reveal strategies for structure-based inhibitor design
View ORCID ProfileMonica Rosas-Lemus1,2,*, View ORCID ProfileGeorge Minasov1,2,*, View ORCID ProfileLudmilla Shuvalova1,2,*, View ORCID ProfileNicole L. Inniss1,2, View ORCID ProfileOlga Kiryukhina1,2, View ORCID ProfileJoseph Brunzelle3, and View ORCID ProfileKarla J. F. Satchell1,2,†
See all authors and affiliations
Science Signaling 29 Sep 2020:
Vol. 13, Issue 651, eabe1202
DOI: 10.1126/scisignal.abe1202
Abstract
There are currently no antiviral therapies specific for SARS-CoV-2, the virus responsible for the global pandemic disease COVID-19. To facilitate structure-based drug design, we conducted an x-ray crystallographic study of the SARS-CoV-2 nsp16-nsp10 2′-O-methyltransferase complex, which methylates Cap-0 viral mRNAs to improve viral protein translation and to avoid host immune detection. We determined the structures for nsp16-nsp10 heterodimers bound to the methyl donor S-adenosylmethionine (SAM), the reaction product S-adenosylhomocysteine (SAH), or the SAH analog sinefungin (SFG). We also solved structures for nsp16-nsp10 in complex with the methylated Cap-0 analog m7GpppA and either SAM or SAH. Comparative analyses between these structures and published structures for nsp16 from other betacoronaviruses revealed flexible loops in open and closed conformations at the m7GpppA-binding pocket. Bound sulfates in several of the structures suggested the location of the ribonucleic acid backbone phosphates in the ribonucleotide-binding groove. Additional nucleotide-binding sites were found on the face of the protein opposite the active site. These various sites and the conserved dimer interface could be exploited for the development of antiviral inhibitors.
